BRIEF published on 06/26/2025 at 10:05, 1 year ago Lupus Alpha Asset Management AG dévoile sa participation dans Alpha Group International plc Code De Prise De Contrôle Formulaire 8.3 Divulgation Des Actions Lupus Alpha Groupe Alpha
PRESS RELEASE published on 06/26/2025 at 10:00, 1 year ago Form 8.3 - Lupus alpha Asset Management AG: Alpha Group International plc Lupus alpha Asset Management AG discloses 1.4481% stake in Alpha Group International plc as of 25th June 2025 Stake Disclosure Lupus Alpha Asset Management AG Alpha Group International Plc 1.4481% 25th June 2025
BRIEF published on 05/23/2025 at 11:45, 1 year 1 month ago Lupus Alpha révèle sa position dans Alpha Group International Actionnariat Code De Prise De Contrôle Divulgation Des Valeurs Mobilières Lupus Alpha Groupe Alpha
BRIEF published on 05/23/2025 at 11:45, 1 year 1 month ago Lupus Alpha Discloses Position in Alpha Group International Takeover Code Securities Disclosure Shareholding Lupus Alpha Alpha Group
PRESS RELEASE published on 05/23/2025 at 11:40, 1 year 1 month ago Form 8.3 - Lupus alpha Asset Management AG: Alpha Group International plc Lupus alpha Asset Management AG discloses a 1.24% stake in Alpha Group International plc as of 22.05.2025. No agreement or arrangement reported Disclosure Lupus Alpha Asset Management AG Alpha Group International Plc 1.24% Stake 22.05.2025
BRIEF published on 05/08/2025 at 12:35, 1 year 1 month ago Lupus Alpha Asset Management AG Discloses Position in Alpha Group International plc Securities Disclosure Takeover Code Lupus Alpha Alpha Group
BRIEF published on 05/08/2025 at 12:35, 1 year 1 month ago Lupus Alpha Asset Management AG dévoile sa participation dans Alpha Group International plc Titres Code De Prise De Contrôle Divulgation Lupus Alpha Groupe Alpha
PRESS RELEASE published on 05/08/2025 at 12:30, 1 year 1 month ago Form 8.3 - Lupus alpha Asset Management AG: Alpha Group International plc Lupus alpha Asset Management AG discloses a 1.247% interest in Alpha Group International plc shares. Form 8.3 filing details ownership positions Form 8.3 Share Disclosure Lupus Alpha Asset Management AG Ownership Positions Alpha Group International Plc
BRIEF published on 05/07/2025 at 14:50, 1 year 1 month ago Lupus Alpha Asset Management AG dévoile sa participation dans Alpha Group International plc Code De Prise De Contrôle Achat D'actions Divulgation Des Valeurs Mobilières Lupus Alpha Asset Management AG Groupe Alpha International
BRIEF published on 05/07/2025 at 14:50, 1 year 1 month ago Lupus Alpha Asset Management AG Discloses Position in Alpha Group International plc Takeover Code Securities Disclosure Share Purchase Lupus Alpha Asset Management AG Alpha Group International
Published on 06/26/2026 at 14:05, 2 hours 18 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 2 hours 23 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 3 hours 23 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 3 hours 38 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 53 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 59 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 1 minute ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 07:00, 9 hours 23 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 9 hours 23 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
